Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017


News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : Could Win a New Roundup Trial -- Update

share with twitter share with LinkedIn share with facebook
share via e-mail
10/10/2018 | 08:58pm EDT

By Jacob Bunge

Bayer AG could win a new trial to defend its Roundup weed killer.

A California judge on Wednesday issued a tentative ruling for a new trial on the $250 million in punitive damages awarded to a groundskeeper, who sought to hold the Roundup maker liable for his non-Hodgkin lymphoma.

If finalized, Judge Suzanne Ramos Bolanos's ruling would grant a motion by Bayer arguing that sum wasn't justified and that the evidence didn't prove the company intended to harm the plaintiff. It isn't clear when the judge may finalize the ruling, issued ahead of a court hearing Wednesday.

The ruling calls into question the bulk of the $289 million judgment, the first in thousands of cases alleging that glyphosate, the main ingredient in Bayer's Roundup herbicide, causes cancer.

The jury verdict rocked Bayer weeks after the German company completed its takeover of Monsanto, the U.S. seed and pesticide giant that manufactures Roundup and crop seeds engineered to withstand the spray. Bayer's stock has fallen about 20% since the verdict, as investors priced in the potential for hundreds of millions of dollars more in court judgments ahead.

The plaintiff, Dewayne Johnson, is likely to appeal the ruling if it is finalized. Representatives for Bayer and Baum Hedlund Aristei & Goldman PC, the law firm representing Mr. Johnson, had no immediate comment.

Glyphosate is the most widely used herbicide in the world, prized for its ability to knock down scores of different weeds. Monsanto pioneered the genetic engineering of corn, soybeans and other crops to survive the chemical, helping simplify farming and turning the "Roundup Ready" franchise into a multibillion-dollar brand. Most of the nearly $11 billion in crop seeds sold annually by Monsanto are genetically modified to resist glyphosate.

The chemical's safety came under global scrutiny after the International Agency for Research on Cancer, a unit of the World Health Organization, in 2015 classified glyphosate as likely having the potential to cause cancer. Monsanto and other agricultural groups pushed back, but the classification prompted a wave of lawsuits and regulatory challenges in the U.S., Europe and elsewhere.

Mr. Johnson's attorneys, Judge Bolanos wrote in the order, didn't provide "clear and convincing evidence of malice or oppression by Monsanto."

A Bayer spokesman said the judge is considering its motions for a new trial on the liability verdicts and reduction of the $39 million in compensatory damages the jury awarded. Bayer "continues to believe that the evidence at trial does not support the verdict and the damage awards, " he said.

A Baum Hedlund spokeswoman declined to comment.

--Sara Randazzo contributed to this article.

Write to Jacob Bunge at jacob.bunge@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER AG
05/24BAYER : announces 5-year partnership with the World Federation of Hemophilia Hum..
05/23BAYER : Donates Hemophilia Treatments in New Partnership
05/21BAYER : hires law firm to probe Monsanto data collection
05/20BAYER : Collaboration to focus on driving novel technologies and applications fo..
05/15BAYER : Investors Fret Over Roundup Liability
05/14GRAIN HIGHLIGHTS : Top Stories of the Day
05/14Materials Up as Trade-War Fears Fade -- Materials Roundup
05/14Factbox - More Roundup trials, appeals in store for Bayer after $2 billion ve..
05/14NEWS HIGHLIGHTS : Top Company News of the Day
05/14NEWS HIGHLIGHTS : Top Company News of the Day
More news
Financials (€)
Sales 2019 46 546 M
EBIT 2019 8 215 M
Net income 2019 3 662 M
Debt 2019 37 837 M
Yield 2019 5,34%
P/E ratio 2019 14,09
P/E ratio 2020 11,55
EV / Sales 2019 1,89x
EV / Sales 2020 1,78x
Capitalization 50 265 M
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 77,7 €
Spread / Average Target 44%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-11.00%56 306
JOHNSON & JOHNSON7.59%368 655
PFIZER-3.89%233 239
ROCHE HOLDING LTD.11.42%233 096
NOVARTIS17.44%219 832